Law360, New York (April 08, 2011, 5:31 PM ET) -- A U.K. appeals court has shot down a bid by Merck & Co. Inc. to revive a European patent covering Cosopt, paving the way for Teva UK Ltd. to push forth a generic version of the glaucoma treatment.
The London-based Court of Appeal said in an opinion published Friday that the Chancery Division of the Patents Court had correctly ruled that Merck's patent was “invalid for want of novelty” and that it “lacked an inventive step.”
Merck was granted a European patent on Cosopt in April...
UK Court Shutters Merck's Cosopt Patent Fight
To view the full article, take a free trial now.
